TYRA
Tyra Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.53
+0.73%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$21.59
From 52W high−45.66%
Volume542625.00
Market cap$1.48B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$21.59
From 52W high
−45.66%
Volume
542625.00
Market cap
$1.48B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.6x
P/E (TTM)
—
RSI (14)
50.2
MomentumView details →
1D Return
+0.73%
YTD Return
−19.13%
SummaryUpdated Jun 1, 2026
Tyra Biosciences, Inc. (NASDAQ:TYRA) is a preclinical-stage biopharmaceutical company founded in 2018 and headquartered in Carlsbad, California. The company went public in September 2021 and focuses on developing innovative cancer therapies designed to overcome tumor resistance mechanisms that limit the effectiveness of existing treatments. Tyra specializes in precision oncology, utilizing its proprietary SNAP platform to design targeted therapies against specific genetic mutations that drive cancer growth and resistance.
Similar companies
Latest newsMore news →
Tyra Biosciences priced an underwritten offering of 9,079,000 common shares at $22.03 per share and pre-funded warrants for 9,078,529 shares at $22.029 each, raising about $400 million.52d agoTyra Biosciences announced initial results from its Phase 2 SURF302 trial of oral dabogratinib, establishing clinical proof of concept and selecting a 60 mg once-daily dose for planned registrational studies.56d ago